Zenith Epigenetics Ltd.
Zenith Epigenetics Ltd is a clinical stage biotechnology company developing best in class bromodomain (BET) inhibitors for the treatment of cancer and other disorders with significant unmet medical needs. Our goal is to be a leading epigenetic company translating BET biology into impactful therapies
Delegate Contacts
As President and CEO of Resverlogix, Mr. McCaffrey spearheaded the development and spin-out of Resverlogix’s subsidiary RVX Therapeutics Inc. to Zenith Epigenetics Corp., a newly-incorporated company. As President and CEO of Zenith Epigenetics, Mr. McCaffrey assembled a world class Oncology team to further the development of this program. In addition to Zenith Epigenetics Corp., Mr. McCaffrey also serves on the Board of Directors of Resverlogix Corp